Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Down 64.3% in July

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the target of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 44,100 shares, a decrease of 64.3% from the June 30th total of 123,400 shares. Based on an average daily volume of 1,314,500 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

Separately, The Goldman Sachs Group began coverage on shares of Bayer Aktiengesellschaft in a research report on Thursday, May 30th. They issued a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating and nine have issued a hold rating to the stock. According to data from MarketBeat, Bayer Aktiengesellschaft presently has an average rating of “Hold”.

Bayer Aktiengesellschaft Stock Performance

OTCMKTS BAYRY traded up $0.02 on Thursday, hitting $7.29. 2,504,586 shares of the company were exchanged, compared to its average volume of 551,981. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.31 and a quick ratio of 0.87. Bayer Aktiengesellschaft has a twelve month low of $6.82 and a twelve month high of $14.70. The company’s 50 day moving average price is $7.32 and its 200-day moving average price is $7.62.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings results on Tuesday, May 14th. The company reported $0.77 earnings per share (EPS) for the quarter. The business had revenue of $14.95 billion for the quarter. Bayer Aktiengesellschaft had a negative net margin of 6.70% and a positive return on equity of 17.57%. Analysts anticipate that Bayer Aktiengesellschaft will post 1.35 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.